文献速递甲状腺疾病

晚期甲状腺未分化癌一线化疗的多中心注册分析

Outcome of first-line chemotherapy for anaplastic thyroid cancer-a multicenter registry analysis.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

德国7家三级中心回顾性注册研究纳入158例经组织学确诊的甲状腺未分化癌(ATC)成人患者,比较一线卡铂/紫杉醇(CP)±放疗与其他细胞毒化疗的结局。CP组与其他化疗组的无进展生存(PFS)和总生存(OS)均无差异,CP未显示生存获益;年龄≥65岁、淋巴结转移和远处转移与更高死亡风险相关,手术与更低死亡风险相关。

要点

  • CP与其他化疗相比,PFS和OS均无显著差异
  • CP未显示OS改善,完全缓解率两组亦无差异
  • 年龄≥65岁、淋巴结转移和远处转移提示更高死亡风险

核心结论

  • 在本注册研究中,CP一线治疗ATC未显示生存获益。
  • 结局取决于疾病负荷和可切除性,强调需要快速分子诊断。
  • 化疗可能作为桥接策略。

研究设计与样本

  • 德国回顾性多中心注册研究,纳入7家三级中心2000-2024年收治的158例经组织学确诊的ATC成人患者,均接受一线细胞毒化疗。
  • 采用Kaplan-Meier法和log-rank检验比较PFS与OS,并用Cox比例风险模型识别风险因素。

主要发现

  • 97例接受一线CP,61例接受其他化疗。
  • 多变量分析中,年龄≥65岁、淋巴结转移和远处转移与更高死亡风险相关;手术与更低死亡风险相关;CP与OS改善无关。
  • 二线治疗中,化疗与激酶抑制±免疫治疗的结局无差异。

临床怎么用

  • CP±放疗可作为ATC一线化疗的可选方案之一,但不应期望其优于其他细胞毒化疗。
  • 治疗决策应结合疾病负荷和可切除性评估,并尽快进行分子检测以指导后续治疗。
  • 化疗可作为桥接策略,为分子诊断和后续治疗争取时间。

局限性

  • 回顾性注册研究设计,可能存在选择偏倚和未测量的混杂因素。
  • 样本量有限(158例),CP组97例、其他化疗组61例。
  • 未报告具体其他化疗方案组成及放疗细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Prognosis of anaplastic thyroid cancer (ATC) remains poor. In the absence of immediately actionable molecular alterations, guidelines recommend multimodal therapy including radiotherapy and cytotoxic chemotherapy, but optimal regimens are not established. Many centers in Germany have adopted carboplatin/paclitaxel (CP), with or without radiotherapy, as a preferred first-line approach. OBJECTIVE: This study aims to compare the outcome of patients treated first-line with CP ± radiotherapy vs other cytotoxic chemotherapy regimens in ATC. DESIGN: Retrospective multicenter registry study in Germany. SETTING AND PATIENTS: 158 adults with histologically confirmed ATC treated with first-line cytotoxic chemotherapy at 7 German tertiary centers (2000-2024). MAIN OUTCOME MEASURES: Progression-free survival (PFS) and overall survival (OS) were compared with Kaplan-Meier and log-rank tests; a Cox proportional hazard model was used to identify risk factors. RESULTS: 97 patients received first-line CP, and 61 received other chemotherapy. PFS (102 vs 89 days; log-rank P = .23) and OS (278 vs 295 days; P = .50) did not differ between CP and other regimens. Complete response occurred in 13% with CP and 8% with other chemotherapy (P = .46). In multivariable analyses, age ≥65 years, lymph node metastasis, and distant metastasis were associated with higher mortality risk. Surgery was associated with a lower mortality risk. CP was not associated with improved OS. The outcome of second-line treatment was not different for chemotherapy vs kinase inhibition ± immunotherapy. CONCLUSION: In this registry study, CP showed no survival benefit in ATC; outcomes depended on disease burden and resectability, underscoring the need for rapid molecular diagnostics. Chemotherapy may serve as a bridging strategy.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Graf KE, Adam P, Megerle F, et al. Outcome of first-line chemotherapy for anaplastic thyroid cancer-a multicenter registry analysis. J Clin Endocrinol Metab. 2026. PMID: 42046902. doi:10.1210/clinem/dgag177

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。